Dual targeting of prosurvival BCL-2 proteins has also been shown to be effective in Ph+ ALL [43, 44], and is worth further investigation in lymphoid BP-CML. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.